Pan-cancer analysis revealed that compared to non-cancerous tissues, AKR1B10 expression was significantly elevated in cholangiocarcinoma (CHOL), hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate cancer (PRAD), and uterine endometrial cancer (UCEC). This evidence concerns the gene AKR1B10 and prostate carcinoma.